European Commission Approves LENVIMA (lenvatinib) Plus KEYTRUDA (pembrolizumab) as First-Line Treatment for Adult Patients With Advanced Renal Cell Carcinoma
Go back to European Commission Approves LENVIMA (lenvatinib) Plus KEYTRUDA (pembrolizumab) as First-Line Treatment for Adult Patients With Advanced Renal Cell Carcinoma| Eisai Co Ltd American Depositary Shares (AMEX: ESALY) | Delayed: 61.51 --0 (-0%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $61.51 | 52 Week High | $67.60 | |||
| Open | $49.73 | 52 Week Low | $53.55 | |||
| Day High | $61.51 | P/E | N/A | |||
| Day Low | $61.51 | EPS | $0.00 | |||
| Volume | 1,907,007 | |||||
